Nuvation Bio NUVB Cash, Cash Equivalents, and Marketable Securities
Cash, Cash Equivalents, and Marketable Securities at other companies
Other financials
Where this comes from
Reported directly by Nuvation Bio in its filing.
Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition.
The official record: Nuvation Bio’s 10-K, filed March 2, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nuvation Bio's cash, cash equivalents, and marketable securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nuvation Bio's cash, cash equivalents, and marketable securities?
- Nuvation Bio (NUVB) reported cash, cash equivalents, and marketable securities of $18.16M in Q4 2025.
- How has Nuvation Bio's cash, cash equivalents, and marketable securities changed year-over-year?
- Nuvation Bio's cash, cash equivalents, and marketable securities decreased by 90.3% year-over-year, from $186.93M to $18.16M.
- What is the long-term trend for Nuvation Bio's cash, cash equivalents, and marketable securities?
- Over 5 years (2020 to 2025), Nuvation Bio's cash, cash equivalents, and marketable securities has grown at a -37.9% compound annual growth rate (CAGR), from $196.4M to $18.16M.
- What does cash, cash equivalents, and marketable securities mean?
- This represents the most liquid assets held by the company, including cash on hand, bank deposits, and short-term investments that can be readily converted into cash. It serves as the primary buffer for operational liquidity and potential capital allocation activities. Investors monitor this to assess the company's ability to meet short-term obligations and fund growth initiatives.